News and Trends 15 Mar 2017
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]